Vincristine sulfate

For research use only. Not for use in humans.

Catalog No.S1241 Synonyms: Leurocristine

35 publications

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vincristine sulfate has been cited by 35 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 M165OWNmdGxiVnnhZoltcXS7IFHzd4F6 MnH2NE0xNjVizszN Mo\pNlQhcA>? MnvT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MXuyOVY3Ozd4OR?=
HepG2-HBV1.1 MUHBdI9xfG:|aYOgRZN{[Xl? NYDQOpk3OC1yLkWg{txO M3Kzc|I1KGh? MnzCbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M1HKXFI2PjZ|N{[5
HepG2.2.15 M1e2c2Z2dmO2aX;uJGF{e2G7 NWT6O2hxOC5zIN88US=> NULve2VyOjRiaB?= MnTKdJJwdW:2ZYOgbIVx[XSrdHnzJGIhfmm{dYOgdJJwfGWrbjDlfJBz\XO|aX;u MUOyOVY3Ozd4OR?=
HepG2-HBV1.1 MXLGeY5kfGmxbjDBd5NigQ>? NEKzbG4xNjFizszN M2rPfFI1KGh? NUnhb|dFeHKxbX;0[ZMhcGWyYYTpeIl{KEJidnnyeZMheHKxdHXpckBmgHC{ZYPzbY9v NXfnTmpIOjV4NkO3Olk>
HepG2-HBV1.1 NIG4Z2tHfW6ldHnvckBCe3OjeR?= NH7DOHUxNjFizszN Mm[wOFghcA>? MXPwdo9ud3SnczDj[YxtKGW6Y4LleIlwdiCxZjDo[ZBifGm2aYOgRkB3cXK3czDueYNt\W:lYYDzbYR{KGmwc4TlZYQhd2ZiaHXwZZRqfGm|IFKgeolzfXNiRHHu[UBx[XK2aXPs[ZM> MVyyOVY3Ozd4OR?=
HepG2-HBV1.1 M2\GSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMlEh|ryP M{\jPVEuPSCm M2rxNYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJJRqdWViZHXw[Y5l\W62bIm= M2fvbVI2PjZ|N{[5
HepG2-HBV1.1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\lNE4yKM7:TR?= MonvNU02KGR? NHvyd5pqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckB1cW2nIHTldIVv\GWwdHz5 NYnkU25NOjV4NkO3Olk>
HepG2-HBV1.1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\CUlAvOSEQvF2= NIXrSVcyOi15MjDo M3rzbYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> M4LIUVI2PjZ|N{[5
HepG2-HBV1.1 NHTJNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID5SJUxNjFizszN MWixNk04OiCq NGrheHBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> M1f2XlI2PjZ|N{[5
Raji MmnhSpVv[3Srb36gRZN{[Xl? Mkm0NE42yqEQvF2= NIHWWGs4OiCq MoKxZYJwdGm|aHXzJIF2fG:yaHHnfeKh NFjtR2UzPTR2NkO3Oy=>
SK-MEL-28  Mo\ESpVv[3Srb36gRZN{[Xl? NF3RdZc{OCCwTR?= M2nJUFYhcA>? M3;Tb4lv\HWlZYOgS|LjiJOPIHPlcIwu[3mlbHWgZZJz\XO2 NWD3WXpxOjV|MUOwNVA>
H157 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHU[m9wUUN3ME2xMlA{KMLzIECuNFQhdWm3Ml2= MlLNNlUzPTd7MUG=
Jurkat NYfWR2tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[xMVMhdk1? MW[0POKhcA>? M4H4ZmROW09? NYnvNoJS\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? MUWyOVE2PjF2Nh?=
CEM MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XueVEuOyCwTR?= M2W0N|Q5yqCq M1zKV2ROW09? M3jCOoRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NVnRTJhSOjVzNU[xOFY>
P12 NUPXcoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki2NU0{KG6P NHPh[5o1QMLiaB?= MWHEUXNQ MVLk[YNz\WG|ZYOgeoli[mynIHPlcIwhdnWvYnXyd{Bld3OnIHTldIVv\GWwdHz5 NWDVXVEyOjVzNU[xOFY>
KB NFrTfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWizOnpRUUN3ME2wMlAxPDliwsGgNE4xODBzIN88US=> MXmyOVA2QDV{Nh?=
KBv200 (ABCB1) M2TrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ntUGlEPTB;MD6zOFYzKMLzIECuNFA3PiEQvF2= NHjDeWQzPTB3OEWyOi=>
SUDHL6  M1[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;rR|HjiIoQvF2= MWi0PE84OiCq NUnGXoE1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NFPwPWozPDl4MU[wOC=>
SUDHL6  M4TiOmZ2dmO2aX;uJGF{e2G7 MVSx5qCK|ryP NH61eYE4OiCq M4S0TIlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? MmjmNlQ6PjF4MES=
HCT-116 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomxS2k2OD13IH7N MXWyOFkzPzh3Nx?=
SKNBe2C NXfsUphjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT1TWM2OD1|Mj64xtE1NjBibl2= NH7EdZczPDl{MUmyNC=>
IGNR91 M3vZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPsWWtKSzVyPUK0MlPDuTFwNzDuUS=> M{PaRlI1QTJzOUKw
SKNAS NXrrXo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwNdMxNE4zKG6P NEK5dHIzPDl{MUmyNC=>
LAN1 NU\KZZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYroWmhNUUN3ME2yMlPDuTBwMjDuUS=> MUOyOFkzOTl{MB?=
SHSY5Y MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRThwMtMxNE43KG6P NVjLS5hlOjR7MkG5NlA>
A549-WT M2DvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;HTWM2OD1zOT60N|chyrFiMD61PVQhKG6P MnPqNlQ5PTh6Mke=
A549-R NI\De2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHL[JE6UUN3ME2xNk4yPzhiwsGgNE4{OzNiIH7N MVSyOFg2QDh{Nx?=
MCF-7-WT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnneZF6UUN3ME2xO{44PTJiwsGgNE4zOThiIH7N M4TWT|I1QDV6OEK3
MCF-7-R NFfmbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\2TWM2OD13LkWzPUDDuSByLkG0OEAhdk1? MonjNlQ5PTh6Mke=
A549-R MVvDfZRwfG:6aXPpeJkhSXO|YYm= M{i5ZmlEPTB;MUKuNVc5KMLzIECuN|M{KG6P NEPnfWMzPDh3OEiyOy=>
MCF-7-R MVXDfZRwfG:6aXPpeJkhSXO|YYm= MVvJR|UxRTVwNUO5JOKyKDBwMUS0JI5O MV[yOFg2QDh{Nx?=
SW620 NH3xSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXW2lEPTB;Nz64NEDDuSByLkC4JI5O NIe5c2UzPDd{NkezPS=>
SW620/AD300 NGKxZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTlyOT62NEDDuSB6LkmxJI5O MlzzNlQ4OjZ5M{m=
HEK293/pcDNA3.1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5TWM2OD1zLkS1JOKyKDBwMkCgcm0> NI\GZXMzPDd{NkezPS=>
HEK293/ABCC1 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF7LkK5JOKyKDJwMEigcm0> MkDWNlQ4OjZ5M{m=
TCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq0eVAzPCCq M2S3R2lEPTB;N{Cgcm0> M2XtclI1PzF4OUS0
TCC NIHuUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK0PEBp MUHJR|UxRTVyIH7N NXj0bppZOjR5MU[5OFQ>
HepG2/ADM MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwN{i2N:KyOC5{M{exJO69VQ>? MX:yOFcxPDV3Nh?=
HepG2 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LIcGlEPTB;MD6wNVE2yrFyLkCwNVch|ryP NIrYe3kzPDdyNEW1Oi=>
MCF-7/ADR M{HRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy3N|hKSzVyPUSuOFgzPsLzMD6yNFcxKM7:TR?= M2DTWFI1PzB2NUW2
MCF-7 M1vFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nnfWlEPTB;MD6wNVU6yrFyLkCwOlIh|ryP MmfKNlQ4ODR3NU[=
A-172  NF;wW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[xNE4yyqEQvF2= NX\FPHNZOjRxN{KgbC=> MWXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 M2\FNFI1PTNyMkO1
U-251MG NXXhRVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHsNE4yyqEQvF2= NYHCeVNWOjRxN{KgbC=> MYHpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NHj4blAzPDV|MEKzOS=>
DLD-1 MYLGeY5kfGmxbjDBd5NigQ>? NF\6cpAyODBibl2= Mnr0OFghcA>? NUntZpVIeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi NF;qfIYzPDRyM{S1Ny=>
CCD18Co M37zbGZ2dmO2aX;uJGF{e2G7 M{SzcFExOCCwTR?= NUXz[WdHPDhiaB?= Moi2dJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh MUGyOFQxOzR3Mx?=
DLD-1 M4XYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPzdI4xNTFyMECgcm0> M{X2O|Q5KGh? NILRUJJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXLxR4FnOjR2MEO0OVM>
CCD18Co MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiwMVExODBibl2= MV:0PEBp M3joSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFi2eXMzPDRyM{S1Ny=>
HepG2 NHizVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWzNlQhcA>? MUHJR|UxRTV{LkZihKnPxE1? MWKyOFM1OTZ6OB?=
HEK293/pcDNA3.1 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEC0xtExNjByMEOg{txO MWeyOFI5PDd6Mx?=
HEK293/MRP1 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEW1xtExNjBzMkCg{txO NXz2cJRzOjR{OES3PFM>
Ramos M3XLSmFxd3C2b4Ppd{BCe3OjeR?= MVuy5qCK|ryP Ml7XOFghcA>? NVLPO2l5cW6mdXPld{A{PC54JdMxNU46OiViYYDvdJRwe2m| MkDYNlQzPTZ2OUG=
NCI-H1299/pcDNA3 M37RemNmdGxiVnnhZoltcXS7IFHzd4F6 MofvNE0zOCCwTR?= NF72TWI6PiCq MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M1P1W|I1OTd5MEGy
H1299/ICAM-3 NVroUmFtS2WubDDWbYFjcWyrdImgRZN{[Xl? NYezfodLOC1{MDDuUS=> NH\IdG86PiCq NUTIN5hYcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mn7mNlQyPzdyMUK=
NCI-H1299/pcDNA3 MXvGeY5kfGmxbjDBd5NigQ>? MonVNU82NzFyL{KwxsBvVQ>? M4XwXFk3KGh? M2jERYlv\HWlZYOgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMuOyxiODygPUwh[W6mIGDBVnA> M{XBcFI1OTd5MEGy
H1299/ICAM-3 M3rFT2Z2dmO2aX;uJGF{e2G7 Mn\ZNU82NzFyL{KwxsBvVQ>? MmPyPVYhcA>? NXvRW|htcW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? NUjucFMxOjRzN{ewNVI>
W1 NF74SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HHeWlEPTB;MD6wNFMzKM7:TR?= Mlm1NlQyPDBzN{[=
W1VR MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mwSGlEPTB;MD6wOVYh|ryP MVuyOFE1ODF5Nh?=
K562 NXrGfIpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEOyJOKyKDBwMECxJEDPxE1? MVSyOFE{PTl|Nx?=
K562/ADR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7Q[2JKSzVyPUOuNlYyKMLzIECuOFEzKM7:TR?= M3jldVI1OTN3OUO3
K562 MVnBdI9xfG:|aYOgRZN{[Xl? MYqwMlMh|ryP M3nkc|I1KGh? NGjQZYZqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M3i3eVI1OTN3OUO3
K562/ADR NGrmW5hCeG:ydH;zbZMhSXO|YYm= NH7LZoM{KM7:TR?= MUCyOEBp MWPpcoR2[2W|IHHwc5B1d3Orcx?= NVvoNXNIOjRzM{W5N|c>
A549 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1WIdxUUN3ME2wMlExKMLzIECuNFMh|ryP NFTOTIwzOzl5MUC3OS=>
K562 NX3sTI5WS2WubDDWbYFjcWyrdImgRZN{[Xl? NHXzNGg{Njd34pETOlDDqG6P M4DpRVczyqCqwrC= NHHKXJZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXiyN|g4PzJ{Mx?=
lucena NGLJfZJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1jkeFMvPzYkgKO2NOKhdk1? Mn3pO|LDqGkEoB?= MYnuc{Bm\m[nY4S= NFnCcFEzOzh5N{KyNy=>
FEPS MlvMR4VtdCCYaXHibYxqfHliQYPzZZk> M{fDfFMvPzYkgKO2NOKhdk1? MUG3NuKhcMLi MYfuc{Bm\m[nY4S= NF\aTWwzOzh5N{KyNy=>
A2780 M{HHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TwRWlEPTB;Mz61JI1O MmHxNlM5Ojl{MEO=
ACHN MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRDBwMTDtUS=> MkjNNlM5Ojl{MEO=
U-937 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r0bGlEPTB:M{Sgcm0> NH7ueGIzOzh{OUKwNy=>
Jurkat M4PBUmFxd3C2b4Ppd{BCe3OjeR?= NVvVZ4h4PcLizsznM41tyqB? M{\4XFI1KGh? M4LX[olv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NHjDdm4zOzhzMESwPS=>
Jurkat NV3PXohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfKbVk2yqEQvHevcYzDqA>? Mk\INlQhcA>? NIS3PINienKnc4SgTpVzc2G2IHPlcIx{KGmwIFeyM20heGijc3W= MV:yN|gyODRyOR?=
Hep-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEVCtVAvODFizszN MmjSNlM4QDB2MkS=
Hep-2/v M17lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXoTWM2OD1zLklCtVAvOjBizszN MUmyN|c5ODR{NB?=
SGC-7901 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBSHYxNTFyIN88[{9udA>? NIezU5IzPC92OD:3NkBp NEG0[FFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NYTjRZBmOjN5NEO1O|I>
SGC-7901/VCR MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W0dFAuOTBizsznM41t MYGyOE81QC95MjDo Mm\ibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MljUNlM4PDN3N{K=
SGC-7901 NEDqZ3dCeG:ydH;zbZMhSXO|YYm= Ml\XbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? MWOyN|c1OzV5Mh?=
SGC-7901/VCR M1LLdGFxd3C2b4Ppd{BCe3OjeR?= MlHSbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? M1:0cFI{PzR|NUey
KB-3-1 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4O5hKSzVyPUGuOlYhyrFiMD6xOlIh|ryP M4fo[VI{Pjd|NES1
KB-C2 M{DyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XvZ2lEPTB;MkCyMlU3KMLzIESyMlQ5OSEQvF2= MnLtNlM3PzN2NEW=
KB-3-1 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PkeGlEPTB;MT6yOkDDuSByLkCyO{DPxE1? MojINlM3PzN2NEW=
KB-V1 NF21RndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[0[mlEPTB;MkC4Mlg2KMLzIEKwMlQh|ryP NIewWXMzOzZ5M{S0OS=>
HEK293/pcDNA3.1 NH;GZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrVTWM2OD1{ND6xJOKyKDBwMkC0JO69VQ>? MVWyN|Y4OzR2NR?=
HEK293/ABCB1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ru[mlEPTB;M{WxNk45KMLzIEO3PE4{QTFizszN MX6yN|Y4OzR2NR?=
A549/EGFP  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLvZmF[OC5yMT2xNFAxKM7:TR?= Mlr6TWM2OD16Nj63JOKyKDJ7LkGg{txO M1v4dlI{PjN2Mkiy
A549/Slug MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3T[FAxNjBzLUGwNFAh|ryP NIDUcXNKSzVyPUmuO{DDuSB|LkGg{txO NXjwe2JvOjN4M{SyPFI>
JFCR39  Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjrenpWOSEEtV2= MXyyOEBp M{foeWROW09? MmLVcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? NYDMUYVkOjN3OUiyO|Y>
A549 MUHGeY5kfGmxbjDBd5NigQ>? NGXBVlIyODBibl2= M3y0RVE3KGh? MXzEUXNQ MVHs[YFleyC2bzDhJIxwe3Nib3[gcYlkem:2dXL1cIV{ MWWyN|U6QDJ5Nh?=
SGC7901 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwMkdihKnDueLCiUCuNVEh|rypL33s NV;XXXdSOjN3NkS0PFI>
SGC7901/LV-NC NE\NZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW4ZZBKSzVyPUGuO|fjiIoEsfMAjVAvOTZizsznM41t NXvzWXNrOjN3NkS0PFI>
SGC7901/LV-SGO1 NETOVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnRTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> MnyxNlM2PjR2OEK=
SGC7901/VCR MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nMR2lEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t MXqyN|U3PDR6Mh?=
SGC7901/VCR-NC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rFfWlEPTB;MUmuPFbjiIoEsfMAjVIvODFizsznM41t MYKyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 NWruNJlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjmTI46UUN3ME22MlE56oDLwsJihKkyNjB|IN88[{9udA>? M3\qe|I{PTZ2NEiy
SGC7901/ADR MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK5coR4UUN3ME23Mlg26oDLwsJihKkxNjZ2IN88[{9udA>? NXu0U2FpOjN3NkS0PFI>
SGC7901/ADR-NC NFfRdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGi3No9KSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MV[yN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2qyfmlEPTB;Mz60OwKBkcLz4pEJNE4zQSEQvHevcYw> NUfiUJp5OjN3NkS0PFI>
SH-SY5Y  M3TpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\rO|AvODBzLUGwJO69VQ>? MoPONlQhcA>? NGTI[YJKSzVyPUCuNVE{yrFyLkCxNkDPxE1? NF3vcFEzOzF{OUC2OS=>
SH-SY5Y  MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2VFAvODBzLUGwJO69VQ>? MkH0OFghcA>? MmTUTWM2OD1yLkC3POKyOC5yMEmg{txO MlXtNlMyOjlyNkW=
SH-SY5Y  NHjpZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W3O|AvODBzLUGwJO69VQ>? NYHWcnZqPzJiaB?= MkXuTWM2OD1yLkC1NeKyOC5yMEig{txO NGX1XYEzOzF{OUC2OS=>
SH-SY5Y MYDBdI9xfG:|aYOgRZN{[Xl? Ml3nNE4yKM7:TR?= M3jwWlAuOjRiaB?= MmDxbY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= MWGyN|EzQTB4NR?=
SH-SY5Y M1PEUmFxd3C2b4Ppd{BCe3OjeR?= MY[wMlEh|ryP MorGNE0zPCCq MV;pcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? NEmxZlEzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1; 

PubMed: 26156322     


MOLT-4 Cells were treated with vincristine (0.3, 1, and 3 nM) alone or co-treated with SAHA (500 nM) for 24 h. Then, total cell lysates were obtained to evaluate the G2/M phase regulatory protein expression and the tubulin acetylation. Data are expressed as mean values ± SD of at least three separate determinations. S SAHA, V vincristine

26156322
Growth inhibition assay
Cell viability ; 

PubMed: 26156322     


MOLT-4 cells were treated with various concentrations of vincristine for 24 and 48 h, respectively.  Cell viability was measured by MTT assay.

26156322
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine
Smiles CCC1(O)CC2CN(CCC3=C([NH]C4=C3C=CC=C4)C(C2)(C(=O)OC)C5=CC6=C(C=C5OC)N(C=O)C7C(O)(C(OC(C)=O)C8(CC)C=CCN9CCC67C89)C(=O)OC)C1.O[S](O)(=O)=O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03981510 Recruiting Diagnostic Test: 3D-Transit Constipation|Childhood Acute Lymphoblastic Leukemia|Neurofibromatosis 1|Chronic Constipation With Overflow University of Aarhus June 2019 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID